Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the BofA Securities 2026 Health Care Conference on May 13, 2026, in Las Vegas. Krish S.

Krystal Biotech delivered strong Q1 2026 results, with Vyjuvek sales up 32% YoY to $116.4M and gross margin expanding to 95%.

PITTSBURGH, April 21, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it will report its first quarter 2026 financial results on Monday, May 4, 2026, ...

Krystal Biotech (NASDAQ:KRYS) reported first-quarter 2026 net revenue of $116.4 million from global sales of VYJUVEK, ...

Moby Strategic Performance and Operational Context. VYJUVEK achieved 9% sequential revenue growth despite typical Q1 insuranc ...

Q VYJUVEK global revenue and $846.7 million since launch Enrollment complete in KB803 (corneal abrasions in DEB patients) registrational study On track for KB803 and KB801 (NK) registrational ...

Nearly three years after a Hooversville man was shot and killed in an alleged property dispute in Shade Township, officials ...

As the San Antonio Spurs close out a strong season, finishing the 2025-26 regular season 62-20, capturing their first ...

Petersburg, consistently identified as a food desert, has a new option, and siblings open luxury creative space. See the ...

Long before today's fast-food giants took over, fried chicken chains were battling for attention nationwide. Many disappeared ...

Krystal Biotech said first-quarter 2026 product revenue rose to $116.4 million, up 32% from $88.2 million a year earlier, as ...

Let’s talk about the elephant in the room, except in this case, the elephant is a tree stump and the room is a specially ...